脱毛症(Alopecia):治療薬開発パイプライン動向(世界、2015年上半期版)

【英語タイトル】Alopecia - Pipeline Review, H1 2015

Global Markets Directが出版した調査資料(GMDHC6154IDB)・商品コード:GMDHC6154IDB
・発行会社(調査会社):Global Markets Direct
・発行日:2015年1月30日
・ページ数:68
・レポート言語:英語
・レポート形式:PDF
・納品方法:Eメール
・調査対象地域:グローバル
・産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD2,000 ⇒換算¥226,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD4,000 ⇒換算¥452,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD6,000 ⇒換算¥678,000見積依頼/購入/質問フォーム
販売価格オプションの説明
※お支払金額:換算金額(日本円)+消費税
※納期:即日~2営業日(3日以上かかる場合は別途表記又はご連絡)
※お支払方法:納品日+5日以内に請求書を発行・郵送(請求書発行日より2ヶ月以内に銀行振込、振込先:三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能)
当調査レポートでは、世界における脱毛症(Alopecia)の治療薬開発パイプライン動向について調査・分析し、企業で開発中の治療薬、大学/研究機関で研究中の治療薬、後期段階の製品、治験段階の製品、初期段階の製品、単剤治療薬/併用治療薬/標的別/作用機序別/投与経路別/分子の種類別治療薬の評価、各薬剤のプロファイル(説明、作用機序、研究開発の進展状況)などのデータをお届けいたします。

・イントロダクション
・脱毛症(Alopecia)の概要
・脱毛症(Alopecia)治療薬の開発
  - パイプライン製品の概要
  - パイプライン製品の比較分析
・企業で開発中の治療薬
・大学/研究機関で研究中の治療薬
・脱毛症(Alopecia)パイプライン製品の概略
  - 後期段階の製品
  - 治験段階の製品
  - 初期段階の製品
・製品
・大学/研究機関別、研究中の製品
・脱毛症(Alopecia)治療薬開発に取り組んでいる企業:企業別製品パイプライン
・脱毛症(Alopecia)治療薬の評価
  - 単剤治療薬
  - 併用治療薬
  - 標的別
  - 作用機序(MoA)別
  - 投与経路(RoA)別
  - 分子の種類別
・各薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況
・パイプライン製品の最新動向
・開発休止中の製品/プロジェクト
・開発が中止された製品
・製品開発のマイルストーン
【レポートの概要】

Alopecia – Pipeline Review, H1 2015

Summary

Global Markets Direct’s, ‘Alopecia – Pipeline Review, H1 2015’, provides an overview of the Alopecia’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Alopecia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alopecia and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Alopecia
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Alopecia and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Alopecia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Alopecia pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Alopecia
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Alopecia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

【レポートの目次】

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 6
Introduction 7
Global Markets Direct Report Coverage 7
Alopecia Overview 8
Therapeutics Development 9
Pipeline Products for Alopecia – Overview 9
Pipeline Products for Alopecia – Comparative Analysis 10
Alopecia – Therapeutics under Development by Companies 11
Alopecia – Therapeutics under Investigation by Universities/Institutes 13
Alopecia – Pipeline Products Glance 14
Late Stage Products 14
Clinical Stage Products 15
Early Stage Products 16
Alopecia – Products under Development by Companies 17
Alopecia – Products under Investigation by Universities/Institutes 18
Alopecia – Companies Involved in Therapeutics Development 19
AndroScience Corporation 19
Bristol-Myers Squibb Company 20
C3 Jian, Inc 21
Follicum AB 22
Kuhnil Pharmaceutical Co., Ltd. 23
Lee’s Pharmaceutical Holdings Limited 24
Panacea Biotec Limited 25
ProCertus BioPharm Inc. 26
Taisho Pharmaceutical Co., Ltd. 27
Tigo GmbH 28
Vida Therapeutics Inc. 29
Alopecia – Therapeutics Assessment 30
Assessment by Monotherapy Products 30
Assessment by Target 31
Assessment by Mechanism of Action 33
Assessment by Route of Administration 35
Assessment by Molecule Type 37
Drug Profiles 39
abatacept (recombinant) – Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
ASCJ-9 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
calcitriol – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
DHL-HisZnNa – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
interferon beta-1b – Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
KI-1104 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
KI-1105 – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Peptide for Alopecia – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Peptide for Alopecia and Chemotherapy Effects – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
ProDermaCel – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Recombinant Peptides for Alopecia – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
Recombinant Proteins to Antagonize IFN-Gamma Receptor for Alopecia Areata and Graft Arteriosclerosis – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
Small Molecule to Inhibit ALK5 for Alopecia and Fibrosis – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Small Molecules to Activate P2Y5 Receptor for Alopecia – Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
Small Molecules to Inhibit Plasminogen Activator Inhibitor-1 for Thromboembolic Disease, PCOS and Alopecia – Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
V-2248 – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ZK-003 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
Alopecia – Recent Pipeline Updates 60
Alopecia – Dormant Projects 63
Alopecia – Discontinued Products 65
Alopecia – Product Development Milestones 66
Featured News & Press Releases 66
Jul 23, 2012: Berg Pharma Launches Clinical Trial On BPM 31543 For Prevention Of Chemotherapy-induced Alopecia 66
Appendix 67
Methodology 67
Coverage 67
Secondary Research 67
Primary Research 67
Expert Panel Validation 67
Contact Us 67
Disclaimer 68

[List of Tables]
Number of Products under Development for Alopecia, H1 2015 9
Number of Products under Development for Alopecia - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 12
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Late Stage Development, H1 2015 14
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Development, H1 2015 16
Products under Development by Companies, H1 2015 17
Products under Investigation by Universities/Institutes, H1 2015 18
Alopecia - Pipeline by AndroScience Corporation, H1 2015 19
Alopecia - Pipeline by Bristol-Myers Squibb Company, H1 2015 20
Alopecia - Pipeline by C3 Jian, Inc, H1 2015 21
Alopecia - Pipeline by Follicum AB, H1 2015 22
Alopecia - Pipeline by Kuhnil Pharmaceutical Co., Ltd., H1 2015 23
Alopecia - Pipeline by Lee's Pharmaceutical Holdings Limited, H1 2015 24
Alopecia - Pipeline by Panacea Biotec Limited, H1 2015 25
Alopecia - Pipeline by ProCertus BioPharm Inc., H1 2015 26
Alopecia - Pipeline by Taisho Pharmaceutical Co., Ltd., H1 2015 27
Alopecia - Pipeline by Tigo GmbH, H1 2015 28
Alopecia - Pipeline by Vida Therapeutics Inc., H1 2015 29
Assessment by Monotherapy Products, H1 2015 30
Number of Products by Stage and Target, H1 2015 32
Number of Products by Stage and Mechanism of Action, H1 2015 34
Number of Products by Stage and Route of Administration, H1 2015 36
Number of Products by Stage and Molecule Type, H1 2015 38
Alopecia Therapeutics - Recent Pipeline Updates, H1 2015 60
Alopecia - Dormant Projects, H1 2015 63
Alopecia - Dormant Projects (Contd..1), H1 2015 64
Alopecia - Discontinued Products, H1 2015 65

[List of Figures]
Number of Products under Development for Alopecia, H1 2015 9
Number of Products under Development for Alopecia - Comparative Analysis, H1 2015 10
Number of Products under Development by Companies, H1 2015 11
Number of Products under Investigation by Universities/Institutes, H1 2015 13
Comparative Analysis by Clinical Stage Development, H1 2015 15
Comparative Analysis by Early Stage Products, H1 2015 16
Assessment by Monotherapy Products, H1 2015 30
Number of Products by Top 10 Targets, H1 2015 31
Number of Products by Stage and Top 10 Targets, H1 2015 32
Number of Products by Top 10 Mechanism of Actions, H1 2015 33
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34
Number of Products by Top 10 Routes of Administration, H1 2015 35
Number of Products by Stage and Top 10 Routes of Administration, H1 2015 36
Number of Products by Top 10 Molecule Types, H1 2015 37
Number of Products by Stage and Top 10 Molecule Types, H1 2015 38

【掲載企業】

AndroScience Corporation
Bristol-Myers Squibb Company
C3 Jian, Inc
Follicum AB
Kuhnil Pharmaceutical Co., Ltd.
Lee's Pharmaceutical Holdings Limited
Panacea Biotec Limited
ProCertus BioPharm Inc.
Taisho Pharmaceutical Co., Ltd.
Tigo GmbH
Vida Therapeutics Inc.

★調査レポート[脱毛症(Alopecia):治療薬開発パイプライン動向(世界、2015年上半期版)] (コード:GMDHC6154IDB)販売に関する免責事項を必ずご確認ください。
★調査レポート[脱毛症(Alopecia):治療薬開発パイプライン動向(世界、2015年上半期版)]についてメールでお問い合わせ


◆H&Iグローバルリサーチのお客様(例)◆